Oncology Update

Oncology Update

Diane M. Otte

education, Patient education, nursing education
ONF 2012, 39(3), 317-318. DOI: 10.1188/12.ONF.317-318

The U.S. Food and Drug Administration (FDA) has approved oral vismodegib (Erivedge™) for the treatment of adult patients with locally advanced basal cell carcinoma who are not candidates for surgery or radiation and for those with metastatic disease. The drug initially was tested at Scottsdale Healthcare in Arizona.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.